Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:alternativeName |
gptkb:BIIB122
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Denali_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
DNL151
|
| gptkbp:intendedUse |
treatment of Parkinson's disease
|
| gptkbp:mechanismOfAction |
LRRK2 inhibitor
|
| gptkbp:partner |
gptkb:Biogen
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
in clinical development
|
| gptkbp:target |
LRRK2 protein
|
| gptkbp:bfsParent |
gptkb:Denali_Therapeutics
|
| gptkbp:bfsLayer |
7
|